Re “Dementia Study Predicts a Surge in Cost and Cases” (front page, April 4):
The projected costs of dementia care are staggering, but this has been known for decades. It’s time we paid more attention to one of the fastest-growing chronic diseases in our country.
The Alzheimer’s Drug Discovery Foundation (ADDF) and BrightFocus Foundation today announced a funding collaboration that will support a Phase I human clinical trial to evaluate the cancer drug bexarotene as a treatment for Alzheimer’s disease.
The Alzheimer’s Drug Discovery Foundation (ADDF) and the Lewy Body Dementia Association (LBDA) have awarded $100,000 each to Omar El-Agnaf, PhD, of United Arab Amirates University and Michelle Mielke, PhD, of Mayo Clinic Rochester to provide one year of support for their research projects focused on developing indicators, or biomarkers, for dementia with Lewy bodies (DLB).
The Alzheimer’s Drug Discovery Foundation (ADDF) announced today that it has awarded $205,260 in funding to CohBar Inc. to develop a novel mitochondrial peptide for the treatment of Alzheimer’s disease (AD). The peptide has been shown to have neuro-protective effects against a variety of AD-related toxic insults, including amyloid-beta.
The Alzheimer’s Drug Discovery Foundation (ADDF), Beyond Batten Disease Foundation (BBDF) and the National Multiple Sclerosis Society today announced a funding collaboration to support the creation of the Collaborative CNS Screening Initiative (CCSI), a central repository of chemical compounds that have shown significant Central Nervous System (CNS) activity.
Howard Fillit, MD, founding Executive Director and Chief Science Officer of the Alzheimer’s Drug Discovery Foundation and George Vradenburg, Chairman of USAgainstAlzheimer’s today issued a joint statement in response to an advisory opinion last week by the Medicare Evidence Development and Coverage Advisory Committee (MEDCAC) that there is insufficient evidence to support Medicare reimbursement for PET amyloid imaging scans in patients with cognitive impairment being evaluated for Alzheimer’s disease.
The Alzheimer’s Drug Discovery Foundation (ADDF) is very pleased that the US Food and Drug Administration (FDA) has approved Amyvid™(florbetapir F18 injection), the first diagnostic test for Alzheimer’s disease. This approval marks an important milestone for early detection, diagnosis, treatment and patient care of Alzheimer’s disease and other cognitive disorders.